{
  "id": 19191582,
  "title": "GLP-1 drugs show lower obesity-related cancer risk than insulin, but not all diabetes treatments",
  "url": "https://urgent.news/2026/11/09/glp-1-drugs-show-lower-obesity-related-cancer-risk-than-insulin-but",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-11-09T18:20:04.000Z",
  "source": {
    "name": "Medical Xpress",
    "slug": "medical-xpress",
    "url": "https://medicalxpress.com/news/2026-11-glp-drugs-obesity-cancer-insulin.html"
  },
  "original_language": "en",
  "account": null,
  "summary": "Years of research point to obesity and type 2 diabetes raising the risk of developing several types of cancer. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), a recent medical breakthrough, were originally developed for blood sugar control or diabetes management and also work overtime promoting weight loss. Scientists are curious to explore whether there are any links between these drugs…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 3,
    "also_reported_by": [
      {
        "outlet": "STAT News",
        "title": "STAT+: FDA warns GLP-1 drugs carry potential risk of rare eye condition",
        "url": "https://urgent.news/2026/11/09/stat-fda-warns-glp-1-drugs-carry-potential-risk-of-rare-eye-condition",
        "published": "2026-11-09T15:56:55.000Z"
      },
      {
        "outlet": "Winnipeg Free Press",
        "title": "FDA adds rare vision-loss warning to popular GLP-1 drugs",
        "url": "https://urgent.news/2026/11/09/fda-adds-rare-vision-loss-warning-to-popular-glp-1-drugs",
        "published": "2026-11-09T20:21:53.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}